New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.

摘要: In past years, there has been considerable pessimism over the role of chemotherapy in non-small cell lung cancers. The was largely derived from fact that alkylating agent-based therapies shortened survival and produced severe side effects. This especially important because vast majority patients (approximately 85%) develop metastatic disease during their course. Randomized trials 1980s showed cisplatin-based improved patient survival, quality life as assessed by patients, relieved symptoms symptomatic patients. When administered on an outpatient basis, it actually lowered total care costs for advanced stage 1990s, five new agents, including two taxanes (paclitaxel, docetaxel), gemcitabine, navelbine, irinotecan, were shown to produce higher response rates longer Phase II compared cisplatin or carboplatin. randomized trials, combinations paclitaxel, vinorelbine with alone combination etoposide. toxicity profile agents is also favorable therapy. Preliminary results earlier stages are encouraging. Thus, currently available given cancer good performance status can improve a similar extent other solid tumors, such small breast cancer.